Details:
Under the agreement, ABL Bio will be responsible for the research, development, and commercialization of bispecific ADCs, designed to overcome the limitations of conventional therapeutic ADCs that target only a single antigen on the targeted cancer cell.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: ABL Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2023
Details:
The financing will be used to advance pipeline of novel phosphatase modulators toward the clinic development by leveraging its unique IGNITE phosphatase drug discovery platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: MRL Ventures Fund
Deal Size: $30.9 million Upfront Cash: Undisclosed
Deal Type: Financing May 02, 2023
Details:
Under the agreement, MacroGenics gained access to Synaffix's clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads, each designed to enable ADCs with best-in-class efficacy and tolerability.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: MacroGenics
Deal Size: $2,200.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 14, 2023
Details:
Under the terms of the licensing agreement, Synaffix will provide access to proprietary Antibody-Drug Conjugate technologies to CKD Pharm, comprising GlycoConnect™, HydraSpace™ and an undisclosed linker-payload from the toxSYN™ platform.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Chong Kun Dang Pharm
Deal Size: $132.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 06, 2023
Details:
Under the terms of the agreement, Merus will lead discovery and early stage research activities while Loxo Oncology at Lilly will be responsible for additional research, development and commercialization activities.
Lead Product(s): Bispecific antibody therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,660.0 million Upfront Cash: $40.0 million
Deal Type: Collaboration January 19, 2021
Details:
Under the agreement, the companies will expand their existing collaboration and jointly continue to develop an oral formulation with an increased bioavailability.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Carna Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 26, 2020